Read Here Why Did BioCryst Stopped Enrollment In BCX9930 Studies In Rare Blood Disorder

BioCryst Pharmaceuticals Inc BCRX has paused enrollment in clinical trials with BCX9930 as the Company investigates elevated serum creatinine levels seen in some patients.
The Company will not enroll new patients in the REDEEM-1, REDEEM-2, or RENEW clinical trials during the investigation.
Patients currently enrolled in the trials are continuing on the study drug.
REDEEM-1 and REDEEM-2 are evaluating the Company's oral Factor D inhibitor, BCX9930 (500 mg bid), in patients with paroxysmal nocturnal hemoglobinuria (PNH). This disorder leads to premature death and impaired production of blood cells.
REDEEM-1 is a randomized, open-label, active, comparator-controlled comparison of the efficacy and safety of BCX9930 monotherapy in approximately 81 PNH patients with an inadequate response to a C5 inhibitor.
Related: BioCryst Shares Gain As Royalty Pharma Buys Additional Interests In BCX9930, Orladeyo.
REDEEM-2 is a randomized, placebo-controlled trial to evaluate the efficacy and safety of BCX9930 as monotherapy versus placebo in approximately 57 PNH patients not currently receiving complement inhibitor therapy.
The Company also has begun patient enrollment for RENEW, a proof-of-concept basket trial of oral BCX9930 (500 mg bid) in complement-mediated renal diseases.
Price Action: BCRX shares are down 33.30% at $11.93 during the market session on the last check Friday.